Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liushen pill for long-term SARS-CoV-2 positive COVID-19 patients
ChiCTR2200057532Phase 4Recruiting
- Sponsor
- Suzhou Fifth People's Hospital
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of liushenwan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Suzhou Fifth People's Hospital. Primary endpoint: Time to turn negative after treatment. Started Feb 2022; status: recruiting.
02
Drugs
liushenwan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200057532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057532.